Dr. Sonali Fonseca is a transformational leader and a visionary growth strategist with proven P&L responsibility. She has extensive experience transforming organizations through a range of strategic levers, including M&A transactions, portfolio optimizations, and international growth initiatives.
Sonali is Vice President, Emerging Businesses at Elutia, a pioneering medical device company. In her role, she led commercial manufacturing of the world’s first drug-eluting biomatrix, an implanted device designed to reduce patient complications and post-surgical infections. This product launched in 2024 and has received rapid market uptake. She also recently led the turnaround and subsequent divestiture of Elutia’s Orthobiologics business, bringing in cash proceeds of up to $35M.
Prior to this, Sonali spearheaded the strategic transformation of Elsevier’s global $500M Clinical Solutions division. She was instrumental in driving growth and played a crucial role in the acquisition and subsequent integration of an oncology platform business.
Sonali also has extensive international experience, working in Canada, Australia and across the United States. During her time at Deloitte, she advised the C-Suite and Boards on organic growth strategy and operational improvement. At PwC, she advised the C-Suite, Private Equity groups and Boards on global M&A transactions with assets valued at $1B+.
Sonali earned a PhD in Pharmaceutical Sciences from the University of Toronto and holds two drug discovery patents. She currently resides with her husband in San Diego, California.